Gene · 2249
Papers3,660
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,660
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Comparative Study on Adipose-Derived Mesenchymal Stem Cells Secretome Delivery Using Microneedling and Fractional CO2 Laser for Facial Skin Rejuvenation. | Clin Cosmet Investig Dermatol | 2023 | 36798539 | PubTator, text mining | PubMed |
| First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. | Target Oncol | 2023 | 36787089 | PubTator, text mining | PubMed |
| Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review. | ADMET DMPK | 2023 | 36778905 | PubTator, text mining | PubMed |
| Immunohistochemical Markers of Temporomandibular Disorders: A Review of the Literature. | J Clin Med | 2023 | 36769438 | PubTator, text mining | PubMed |
| Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). | Int J Mol Sci | 2023 | 36769284 | PubTator, text mining | PubMed |
| Mesenchymal Stem Cells and Their Exocytotic Vesicles. | Int J Mol Sci | 2023 | 36768406 | PubTator, text mining | PubMed |
| Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma. | Cancers (Basel) | 2023 | 36765676 | PubTator, text mining | PubMed |
| GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1. | BMC Cancer | 2023 | 36765275 | PubTator, text mining | PubMed |
| Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise. | World J Hepatol | 2023 | 36744169 | PubTator, text mining | PubMed |
| PSC-derived intestinal organoids with apical-out orientation as a tool to study nutrient uptake, drug absorption and metabolism. | Front Mol Biosci | 2023 | 36743212 | PubTator, text mining | PubMed |
| Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections. | Mol Biotechnol | 2023 | 36719639 | PubTator, text mining | PubMed |
| Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma. | Cell Mol Gastroenterol Hepatol | 2023 | 36708970 | PubTator, text mining | PubMed |
| In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice. | Nat Biotechnol | 2023 | 36702898 | PubTator, text mining | PubMed |
| FGF4 improves hepatocytes ferroptosis in autoimmune hepatitis mice via activation of CISD3. | Int Immunopharmacol | 2023 | 36702076 | PubTator, text mining | PubMed |
| Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity. | Stem Cell Res Ther | 2023 | 36691086 | PubTator, text mining | PubMed |
| Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. | Lancet Oncol | 2023 | 36681091 | PubTator, text mining | PubMed |
| Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update. | Cancers (Basel) | 2023 | 36672443 | PubTator, text mining | PubMed |
| Extracellular Vesicles: New Classification and Tumor Immunosuppression. | Biology (Basel) | 2023 | 36671802 | PubTator, text mining | PubMed |
| The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies. | Curr Oncol | 2023 | 36661697 | PubTator, text mining | PubMed |
| Controlling human organoid symmetry breaking reveals signaling gradients drive segmentation clock waves. | Cell | 2023 | 36657441 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2249/papers?page=19